El Ansari et al. showed that high expression of SLC7A5 was associated with poor prognosis and poor survival outcome in the highly proliferative ER+ BC subtype (luminal B), indicating its role in the progression of the aggressive ER+ subtype and as a key therapeutic target [34]. The gene discussed is ESR1; the disease is breast cancer.